Report overview
Multi-cancer early detection (MCED) tests are?tests that measure biological signals in body fluids that may be shed by cancer cells. These signals are also known as biomarkers or tumor markers. MCED tests are being developed to screen for cancers from more than one organ site at the same time.
This report contains market size and forecasts of Multi Cancer Early Detection in Global, including the following market information:
Global Multi Cancer Early Detection Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Multi Cancer Early Detection market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Liquid Biopsy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Multi Cancer Early Detection include Grail, LLC (Illumina, Inc.), Exact Sciences Corporation., Foundation Medicine, Inc., AnchorDx, Guardant Health, Inc., Burning Rock Biotech Limited, GENECAST, Laboratory for Advanced Medicine, Inc. and Singlera Genomics Inc., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Multi Cancer Early Detection companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multi Cancer Early Detection Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Multi Cancer Early Detection Market Segment Percentages, by Type, 2022 (%)
Liquid Biopsy
Gene Panel, LDT & Others
Global Multi Cancer Early Detection Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Multi Cancer Early Detection Market Segment Percentages, by Application, 2022 (%)
Hospitals
Diagnostic Laboratories
Others
Global Multi Cancer Early Detection Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Multi Cancer Early Detection Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multi Cancer Early Detection revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Multi Cancer Early Detection revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Grail, LLC (Illumina, Inc.)
Exact Sciences Corporation.
Foundation Medicine, Inc.
AnchorDx
Guardant Health, Inc.
Burning Rock Biotech Limited
GENECAST
Laboratory for Advanced Medicine, Inc.
Singlera Genomics Inc.
